Correction to: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies (Nature Communications, (2022), 13, 1, (5313), 10.1038/s41467-022-32960-3)

Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang*, Marcel R.M. van den Brink*, Ming D. Li*, He Huang*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-022-32960-3, published online 09 September 2022 The original version of this Article had numerical mistakes in the source data corresponding to figure 1a, some values (or textual entries) were missing (cells 1P, 18P), and some were incorrect (cells 3Q, 4J, 11J-P, 17K-L, 18N, 30B, 30E, 30J-K, 30N, 39E, 39J, 40E, 40J, 41E, 54J, 63J-L, 65B, 65K, 65N, 73E, 73J, 74E, 74J, 78N-P, 85J). These are replaced with the correct entries. Column B of the source data corresponding to Supplementary Table 1 is now deleted, due to confidentiality concerns. Accordingly, the text of the “Clinical trial outcomes” section of the Results has been corrected: Line 10: “Within 1 month after BCMA CAR-T cell infusion, 2 patients died of cerebral hemorrhage and 4 died of severe infections. Of the 95 evaluable patients, 91 (95.8%) had an overall response.” Line 13: “With a median follow-up time of 21.2 months (95% CI, 18.4–32.1), the median progression-free survival (PFS) was 12.0 (95% CI, 8.1–15.7) months. The 1-year OS and PFS rates were 0.70 (95% CI, 0.61–0.80) and 0.48 (95% CI, 0.39–0.59), respectively.

Original languageEnglish
Article number2678
JournalNature Communications
Volume15
Issue number1
DOIs
StatePublished - Dec 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction to: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies (Nature Communications, (2022), 13, 1, (5313), 10.1038/s41467-022-32960-3)'. Together they form a unique fingerprint.

Cite this